APPENDIX IA

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Notes:

(a)

(b)

Amount represents trade payable to United-Power Pharma Tech Co., Ltd. (“UPPT”), an associate of
BJZD.

Included in the amount is other payables to BJZD. The amount is unsecured, interest free and repayable
on demand.

Payment terms with suppliers are mainly with credit term of 30 days from the time when the goods and services
are received from the suppliers. The following is an aging analysis of trade payables and notes payables presented
based on invoice date at the end of the reporting period:

0 to 30 days
31 to 60 days
61 to 180 days
Over 180 days

16A. CONTRACT LIABILITIES

Amounts received in advance of delivery of biological reagent
Upfront fee received for collaboration agreement

Current
Non-current

As at
September 30,
2018

RMB’000
(Unaudited)

As at
December 31,
2017

RMB’000
(Audited)

11,196
1
5,561
10,768

27,526

15,289
207
209
601

16,306

As at
September 30,
2018

RMB’000
(Unaudited)

As at
December 31,
2017

RMB’000
(Audited)

–
28,302

28,302

–
28,302

28,302

646
–

646

646
–

646

In June 2018,

the Group entered into a co-development and strategic collaboration agreement

(the
“Agreement”) with CSPC Pharmaceutical Group Limited (“CSPC”), under which the Group and CSPC will
co-develop PD-1 (the anti-PD-1 monoclonal antibody exclusively supplied by the Group), in combination with
albumin-bonded paclitaxel (the “Product”) for the treatment of breast cancer in PRC including Hong Kong, Taiwan
and Macau. A joint steering committee will be established with equal representation from each party to coordinate
and oversee development and commercialisation activities and decisions for the Product. CSPC at its own expense,
shall be responsible for designing and executing the clinical
trial for the Product, supplying albumin-bonded
paclitaxel to the Group for conducting clinical trials, applying and securing approval and commercialisation of the
Product. The Group shall be responsible for securing approval of PD-1 single treatment, supplying PD-1 to CSPC for
conducting clinical trials and supplying PD-1 to CSPC for sale of the Product. All intellectual property rights related
to the Product shall be jointly owned by the Group and CSPC. Further, CSPC was granted an exclusive royalty based
license to commercialise the Product within the PRC from the receipt of the relevant regulatory approval in the PRC
for 20 years (“Commercialisation Period”). On July 11, 2018, the Group received RMB30,000,000 upfront fee

– IA-18 –

